129 related articles for article (PubMed ID: 4203573)
1. Halofenate: an effective hypolipemia- and hypouricemia-inducing drug.
Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
Curr Ther Res Clin Exp; 1973 Dec; 15(12):902-6. PubMed ID: 4203573
[No Abstract] [Full Text] [Related]
2. [First clinical experiences in therapy of hyperuricemia and hyperlipidemia with the clofibrate derivative MK 185].
Wolfram G; Keller C; Kilani C; Zöllner N
Verh Dtsch Ges Inn Med; 1973; 79():1291-3. PubMed ID: 4597609
[No Abstract] [Full Text] [Related]
3. Long-term effect of halofenate on serum lipids.
Aronow WS; Vangrow J; Pagano J; Khemka M; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1974 Sep; 16(9):897-903. PubMed ID: 4214664
[No Abstract] [Full Text] [Related]
4. Long-term efficacy of halofenate on serum triglyceride levels.
Aronow WS; Vicario MD; Moorthy K; King J; Vawter M; Papageorge's NP
Curr Ther Res Clin Exp; 1975 Dec; 18(6):855-61. PubMed ID: 813950
[No Abstract] [Full Text] [Related]
5. [Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate].
Keller C; Wolfram G; Zöllner N
Arzneimittelforschung; 1976; 26(12):2221-4. PubMed ID: 798591
[TBL] [Abstract][Full Text] [Related]
6. Effects of halofenate and probenecid on serum lipids and uric acid in hyperlipidemic, hyperuricemic adults.
Bassett DR; Mikkelsen WM; Buckingham RB; Block WD; Sidiq M; Shakibai A; DiGaetano R; Liou LL
Clin Pharmacol Ther; 1977 Sep; 22(3):340-51. PubMed ID: 330079
[No Abstract] [Full Text] [Related]
7. The metabolic spectrum of halofenate.
Ryan JR
Int J Clin Pharmacol Biopharm; 1975 Jul; 12(1-2):239-43. PubMed ID: 51838
[TBL] [Abstract][Full Text] [Related]
8. Effect of halofenate on serum uric acid.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP
Clin Pharmacol Ther; 1973; 14(3):371-3. PubMed ID: 4572799
[No Abstract] [Full Text] [Related]
9. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
Krut LH; Seftel HC; Joffe BI
S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
[TBL] [Abstract][Full Text] [Related]
10. One-year trials with halofenate, clofibrate, and placebo.
Dujovne CA; Azarnoff DL; Huffman DH; Pentikäinen P; Hurwitz A; Shoeman DW
Clin Pharmacol Ther; 1976 Mar; 19(3):352-9. PubMed ID: 177242
[TBL] [Abstract][Full Text] [Related]
11. A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).
Neuman J; de Neuman MP; Talmasky S; Pesce R; Valero E; Martiarena JL
J Cardiovasc Surg (Torino); 1973; Spec No():532-7. PubMed ID: 4377715
[No Abstract] [Full Text] [Related]
12. Effect of halofenate on serum lipids.
Aronow WS; Harding PR; Khursheed M; Vangrow JS; Papageorge's NP; Mays J
Clin Pharmacol Ther; 1973; 14(3):358-65. PubMed ID: 4572798
[No Abstract] [Full Text] [Related]
13. A two-year crossover therapeutic trial with halofenate and clofibrate.
Dujovne CA; Azarnoff DL; Pentikainen P; Manion C; Hurwitz A; Hassanein K
Am J Med Sci; 1976; 272(3):277-84. PubMed ID: 797258
[TBL] [Abstract][Full Text] [Related]
14. Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia.
Feldman EB; Gluck FB; Carter AC
J Clin Pharmacol; 1978; 18(5-6):241-8. PubMed ID: 346616
[TBL] [Abstract][Full Text] [Related]
15. Studies of the uricosuric action of the hypolipidemic drug halofenate.
Ravenscroft PJ; Sands JM; Emmerson BT
Clin Pharmacol Ther; 1973; 14(4):547-51. PubMed ID: 4723262
[No Abstract] [Full Text] [Related]
16. Potentiation of hypoglycemic effect of sulfonylureas by halofenate.
Jain AK; Ryan JR; McMahon FG
N Engl J Med; 1975 Dec; 293(25):1283-6. PubMed ID: 171574
[TBL] [Abstract][Full Text] [Related]
17. [Therapy of hyperlipidemia. Clinical experience with clinofibrate].
Avellone G; Di Garbo V; Strano A
Clin Ter; 1989 Apr; 129(1):25-9. PubMed ID: 2525449
[TBL] [Abstract][Full Text] [Related]
18. [Procetofen, a new lipid- and urine-acid-reducing substance].
Matzkies F; Schulzky D; Berg G
Fortschr Med; 1978 Oct; 96(38):1939-41. PubMed ID: 700582
[TBL] [Abstract][Full Text] [Related]
19. Halofenate, serum lipids, and exercise performance in coronary heart disease.
Aronow WS; Vangrow JS; Nelson WH; Pagano J; Papageorge's NP; Khursheed M; Harding PR; Khemka M
Clin Pharmacol Ther; 1974 Jan; 15(1):67-72. PubMed ID: 4587107
[No Abstract] [Full Text] [Related]
20. The uricosuric action of halofenate (MK-185) in patients with hyperuricemia or uncomplicated primary gout and hyperlipidemia.
Hutchison JC; Wilkinson WH
Atherosclerosis; 1973; 18(3):353-62. PubMed ID: 4584481
[No Abstract] [Full Text] [Related]
[Next] [New Search]
